This certified AMA activity will highlight the practice-changing updates in the frontline treatment of relapsed/refractory multiple myeloma (RR/MM) and provide guidance on effective implementation of new evidence through expert-guided discussions and interactive case scenarios.
This activity is intended for HCPs that specialize in hematology/oncology and their treatments teams who treat/manage patients with multiple myeloma (MM).
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Practice Point Communications. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material activity for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHYSICIAN ASSITANTS, NURSE PRACTIONERS, NURSES AND OTHER HEALTHCARE PROFESSIONALS
Physician Assistants (AAPA), Nurse Practitioners (AANP), and Nurses (ANCC) can count ACCME activities certified for AMA PRA Category 1 Credit™ for professional credit reporting purposes. All healthcare professionals, other than physicians, should inquire with their respective certifying or licensing boards to confirm.
MITIGATION OF CONFLICT OF INTEREST
The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.
DISCLOSURE OF RELATIONSHIPS WITH INELIGIBLE COMPANIES
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.
The faculty and planners reported the following financial relationships, or relationships to products or devices, they have with ineligible companies (commercial interests) related to the content of this CME activity.
DISCLOSURES
The speakers and planning committee members listed below have stated they have no relevant relationships to disclose.
Susan Tyler, Ph.D
Robert Ellis, MD
Heather Muskopf
Nirupama Mulherkar
Jill Valone
Martin Stevens
FACULTY DISCLOSURES
Jesus Berdeja, MD
Research Funding: 2Seventy Bio, Abbvie, Acetylon, Amgen, Bluebird Bio, Bristol Myers Squibb, C4 Therapeutics, CaRsgen, Cartesian Therapeutics, Celgene, Celularity, CRISPR Therapeutics, EMD Sorono, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Karyopharm, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva, Zentalis
Consultant: Bluebird Bio, Bristol Myers Squibb, Celgene, CRISPR Therapeutics, Janssen, Kite Pharma, Legend Biotech, Secure Bio, Takeda
Paul Richardson, MD
Research Funding: Bristol Myers Squibb, Celgene, Karyopharm, Oncopeptides, Takeda
Consultant: AstraZeneca, Bristol Myers Squibb, Celgene, GSK, Janssen, Karyopharm, Oncopeptides, Sanofi, Secura Bio, Takeda
Saad Usmani, MD
Researcher: Abbvie, Amgen, Bristol Myers Squibb, Celgene, Gilead, GSK, Janssen, Merck, Sanofi, Seattle Genetics, Skyline DX, Teneobio
Advisory Board: Abbvie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Gilead, GSK, Janssen, Merck, Oncopeptides, Sanofi, Seattle Genetics, Securabio, Skyline DX, Tenebio
Speaker: Amgen, Bristol Myers Squibb, Celgene, Janssen, Sanofi
DISCLAIMER
The opinions expressed during this activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati and Practice Point Communications. The information is presented for the purpose of advancing the attendees’ professional development.
PRIVACY POLICY
The University of Cincinnati and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The University of Cincinnati and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
The University of Cincinnati and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
COPYRIGHT INFORMATION
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
HARDWARE/SOFTWARE REQUIREMENTS
Computer:
- Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
- Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
- Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.
Software/Browser:
- Windows 7 or above running Internet Explorer 10 or above.
- MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
- A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.
Mobile Device:
- Any Apple iPad or iPad Mini running iOS 7.1 or above.
- Android tablets such as the Kindle Fire or Samsung Galaxy S.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
Supported by independent educational grants from Bristol Myers Squibb and Janssen Pharmaceuticals